Pacific Edge's Medicare Coverage Determination Status

Pacific Edge (ASX: $PEB) is awaiting the finalization of the Local Coverage Determination (LCD) 'Genetic Testing for Oncology' by Novitas, the Medicare Administrative Contractor (MAC) responsible for Pacific Edge's US lab. The company expected the LCD to be finalized within 365 days of initial posting, but Novitas has notified that a timeframe for finalization is currently unavailable. As a result, Pacific Edge's tests Cxbladder Triage, Detect, and Monitor continue to receive reimbursement from Medicare and Medicare Advantage payers in line with historical rates and medical necessity guidelines.

Executive Commentary on Medicare Coverage Determination

Pacific Edge continues to anticipate the finalization of the LCD by Novitas, although the specific timeline remains uncertain. The company will provide updates to shareholders as soon as there is clarity on the status of the LCD and its resolution timeline. Until then, Pacific Edge will refrain from further comments on the matter. This ongoing discussion with Novitas and the CMS does not impact the reimbursement of Pacific Edge's tests by Medicare and Medicare Advantage payers, ensuring continued access for patients in need of bladder cancer diagnostic and prognostic tests.

Summary of Pacific Edge's Medicare Coverage Determination Status

Pacific Edge (ASX: $PEB) is currently awaiting the finalization of the Local Coverage Determination (LCD) 'Genetic Testing for Oncology' by Novitas, the Medicare Administrative Contractor (MAC) responsible for the company's US lab. The company's tests Cxbladder Triage, Detect, and Monitor continue to receive reimbursement from Medicare and Medicare Advantage payers in line with historical rates and medical necessity guidelines. Pacific Edge anticipates updates on the status and resolution timeline of the LCD and will keep shareholders informed. The ongoing discussion with Novitas and the CMS does not impact the reimbursement of Pacific Edge's tests, ensuring continued access for patients in need of bladder cancer diagnostic and prognostic tests.